TG-N has been developed for nerve regeneration and involves stimulation of nerve cell growth and prevention of the body’s immune system from causing further damage to nerve tissue. TissueGene is currently evaluating several methods for regenerating nerve tissue including a cell-mediated gene therapy, a protein translocation domain (PTD)-conjugate and various protein growth factor applications for prevention of nerve degeneration. Specifically, TissueGene is exploring the possibility of utilizing systems designed for the directed transport of fusion proteins containing translocation domains.
Technology Platform: Cell therapy and protein therapeutics
Function: Nerve regeneration
Indication: Spinal cord injury and peripheral nerve damage
Development Stage: R&D